{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:29:58Z","timestamp":1761272998465,"version":"build-2065373602"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Myeloid and\/or lymphoid neoplasms with eosinophilia\n                      <jats:italic>PDGFRA<\/jats:italic>\n                      gene fusions usually occur with\n                      <jats:italic>FIP1L1<\/jats:italic>\n                      as the partner gene; however, novel partners have been described. These novel partners are sometimes responsive to tyrosine kinase inhibitor therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      We describe here a patient with a\n                      <jats:italic>PDGFRA<\/jats:italic>\n                      fusion with a previously undescribed partner gene,\n                      <jats:italic>BMP2K<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RNA sequencing with the Archer Fusion Plex Pan Solid Tumor Panel (IDT) was used to detect fusions. DNA sequencing using a custom IDT panel was also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An in-frame\n                      <jats:italic>BMP2K::PDGFRA<\/jats:italic>\n                      fusion was detected in a patient who had an ill-defined myeloid neoplasm with eosinophilia. The myeloid neoplasm had a prominent mast cell component and myeloid blast component in the lymph node, while the bone marrow showed hypercellularity, eosinophilia, and myelofibrosis. DNA NGS revealed a pathogenic TP53 mutation but was negative for mutations in other genes including KIT, JAK2, CALR, and MPL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Given that\n                      <jats:italic>PDGFRA<\/jats:italic>\n                      fusions with novel fusion partners may respond to tyrosine kinase inhibitor therapy, partner agnostic testing methods should be considered either up front or as reflex testing in patients with myeloid and\/or lymphoid neoplasms with blood, bone marrow, or tissue eosinophilia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12308-025-00661-7","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:26:19Z","timestamp":1761272779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel BMP2K::PDGFRA fusion in an unusual myeloid\/lymphoid neoplasm with eosinophilia"],"prefix":"10.1007","volume":"18","author":[{"given":"Ravi Tej","family":"Bommu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila O.","family":"Mnayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrnoosh","family":"Tashakori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-9930","authenticated-orcid":false,"given":"Sophia","family":"Yohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"5","key":"661_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/ejh.12576","volume":"95","author":"T Cluzeau","year":"2015","unstructured":"Cluzeau T, Lippert E, Cayuela JM, Maarek O, Migeon M, Noguera ME, Dombret H, Rea D (2015) Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy. Eur J Haematol 95(5):480\u2013483. https:\/\/doi.org\/10.1111\/ejh.12576","journal-title":"Eur J Haematol"},{"issue":"1","key":"661_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2141.2007.06628.x","volume":"138","author":"CE Curtis","year":"2007","unstructured":"Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, Minervini MM, Stewart J, Reiter A, Cross NC (2007) Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138(1):77\u201381. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06628.x","journal-title":"Br J Haematol"},{"issue":"5","key":"661_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3324\/haematol.2009.016345","volume":"95","author":"P Erben","year":"2010","unstructured":"Erben P, Gosenca D, M\u00fcller MC, Reinhard J, Score J, Del Valle F, Walz C, Mix J, Metzgeroth G, Ernst T, Haferlach C, Cross NC, Hochhaus A, Reiter A (2010) Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 95(5):738\u2013744. https:\/\/doi.org\/10.3324\/haematol.2009.016345","journal-title":"Haematologica"},{"issue":"10","key":"661_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/gcc.20359","volume":"45","author":"C Walz","year":"2006","unstructured":"Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, Lengfelder E, Erben P, M\u00fcller MC, Haferlach T, Hochhaus A, Hehlmann R, Cross NC, Reiter A (2006) Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 45(10):950\u2013956. https:\/\/doi.org\/10.1002\/gcc.20359","journal-title":"Genes Chromosomes Cancer"},{"issue":"21","key":"661_CR5","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1038\/sj.onc.1204369","volume":"20","author":"JM Varley","year":"2001","unstructured":"Varley JM, Attwooll C, White G, McGown G, Thorncroft M, Kelsey AM, Greaves M, Boyle J, Birch JM (2001) Characterization of germline TP53 splicing mutations and their genetic and functional analysis. Oncogene 20(21):2647\u20132654. https:\/\/doi.org\/10.1038\/sj.onc.1204369","journal-title":"Oncogene"},{"issue":"10","key":"661_CR6","doi-asserted-by":"publisher","first-page":"7701","DOI":"10.18632\/oncotarget.3116","volume":"6","author":"AY Saiki","year":"2015","unstructured":"Saiki AY, Caenepeel S, Cosgrove E, Su C, Boedigheimer M, Oliner JD (2015) Identifying the determinants of response to MDM2 inhibition. Oncotarget 6(10):7701\u20137712. https:\/\/doi.org\/10.18632\/oncotarget.3116","journal-title":"Oncotarget"},{"issue":"9","key":"661_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00277-014-2085-1","volume":"93","author":"J Iwasaki","year":"2014","unstructured":"Iwasaki J, Kondo T, Darmanin S, Ibata M, Onozawa M, Hashimoto D, Sakamoto N, Teshima T (2014) FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia. Ann Hematol 93(9):1473\u20131481. https:\/\/doi.org\/10.1007\/s00277-014-2085-1","journal-title":"Ann Hematol"},{"issue":"5","key":"661_CR8","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1093\/labmed\/lmac010","volume":"53","author":"JC Dalland","year":"2022","unstructured":"Dalland JC, Blackburn PR, Reichard KK, Johnson SH, Smadbeck JB, Vasmatzis G, Hoppman NL, Xu X, Greipp PT, Baughn LB, Peterson JF (2022) A novel USP25::PDGFRA gene fusion in a 78 year old patient with a myeloid neoplasm. Lab Med 53(5):e134\u2013e138. https:\/\/doi.org\/10.1093\/labmed\/lmac010","journal-title":"Lab Med"},{"issue":"1","key":"661_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/gcc.20014","volume":"40","author":"AM Safley","year":"2004","unstructured":"Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ, Goodman BK (2004) Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 40(1):44\u201350. https:\/\/doi.org\/10.1002\/gcc.20014","journal-title":"Genes Chromosomes Cancer"},{"issue":"45","key":"661_CR10","doi-asserted-by":"publisher","first-page":"42213","DOI":"10.1074\/jbc.M106163200","volume":"276","author":"AE Kearns","year":"2001","unstructured":"Kearns AE, Donohue MM, Sanyal B, Demay MB (2001) Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro. J Biol Chem 276(45):42213\u201342218. https:\/\/doi.org\/10.1074\/jbc.M106163200","journal-title":"J Biol Chem"},{"issue":"24","key":"661_CR11","doi-asserted-by":"publisher","first-page":"e29179","DOI":"10.1097\/MD.0000000000029179","volume":"101","author":"L Gao","year":"2022","unstructured":"Gao L, Xu Y, Weng LC, Tian ZG (2022) A rare cause of persistent leukocytosis with massive splenomegaly: myeloid neoplasm with BCR-PDGFRA rearrangement-case report and literature review. Medicine (Baltimore) 101(24):e29179. https:\/\/doi.org\/10.1097\/MD.0000000000029179","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"661_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/sj.leu.2404154","volume":"20","author":"J Score","year":"2006","unstructured":"Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, Cross NC (2006) Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20(5):827\u2013832. https:\/\/doi.org\/10.1038\/sj.leu.2404154","journal-title":"Leukemia"},{"issue":"10","key":"661_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.cancergen.2015.07.001","volume":"208","author":"Y Sugimoto","year":"2015","unstructured":"Sugimoto Y, Sada A, Shimokariya Y, Monma F, Ohishi K, Masuya M, Nobori T, Matsui T, Katayama N (2015) A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia. Cancer Genet 208(10):508\u2013512. https:\/\/doi.org\/10.1016\/j.cancergen.2015.07.001","journal-title":"Cancer Genet"},{"issue":"2","key":"661_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/leu.2008.310","volume":"23","author":"C Walz","year":"2009","unstructured":"Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G, Cross NC, Reiter A, LeukemiaNet E (2009) The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia 23(2):271\u2013278. https:\/\/doi.org\/10.1038\/leu.2008.310","journal-title":"Leukemia"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00661-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:26:20Z","timestamp":1761272780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00661-7","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"type":"print","value":"1868-9256"},{"type":"electronic","value":"1865-5785"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a case report, our institution does not require formal approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient is deceased but signed a consent form agreeing to research prior to her death.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The patient is deceased but signed a consent form agreeing to research prior to her death.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"48"}}